UBS AM’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
UBS AM's ACRS Position: Q3 2026 in Review
UBS AM opened a new position in Aclaris Therapeutics (ACRS) in Q3 2026: 4,267 shares worth $22.4K. The stake represents ﹤0.01% of the portfolio and ranks #3619 among its holdings. This is a return to the name: UBS AM previously reported a position in ACRS as recently as Q4 2023.
UBS AM first reported a position in ACRS in Q2 2017 and has held it in 16 quarters since. The position peaked at $6.03M in Q3 2017. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- UBS AM held 4,267 shares of Aclaris Therapeutics worth $22.4K as of Q3 2026.
- Aclaris Therapeutics was a new UBS AM position in Q3 2026.
- Aclaris Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3619 holding.
- UBS AM first reported a position in Aclaris Therapeutics in Q2 2017 and has held it in 16 quarters since.
- UBS AM's Aclaris Therapeutics position peaked at $6.03M in Q3 2017.
- 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.